tradingkey.logo

Life sciences technology firm Rapid Micro's Q4 preliminary revenue rises

ReutersJan 13, 2026 9:24 PM


Overview

  • Life sciences tech firm's preliminary Q4 revenue up 37%, slightly beating analyst expectations

  • Company received record order from top biopharma client for global manufacturing automation

  • Preliminary full-year 2025 revenue grew 20%


Outlook

  • Rapid Micro Biosystems expects full-year 2025 revenue of approximately $33.6 mln

  • Company anticipates continued growth in 2026 supported by strategic partnerships


Result Drivers

  • RECORD ORDER - Co received record multi-system order from a top biopharma client for global manufacturing automation

  • SYSTEM PLACEMENTS - Placement of 16 new Growth Direct systems in Q4 contributed to revenue growth


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Revenue

Slight Beat*

$11.30 mln

$11.20 mln (4 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 160.6% above its January 12 closing price of $3.07

Press Release: ID:nGNX6KPRbP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI